Patterns of initial antibiotic therapy for complicated skin and skin structure infections (cSSSI) in US hospitals, 2000-2009

Infectious Diseases in Clinical Practice

Volumn 21, Issue 3, 2013, Pages 159-167

  Berger, Ariel ^a   Edelsberg, John ^a   Oster, Gerry ^a   Huang, Xingyue ^b   Weber, David J ^c  

^a POLICY ANALYSIS INC PAI   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antibacterial agents; Antibiotics; Clinical practice patterns; Infectious; Skin diseases; Soft tissue infections

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NAFCILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; SKIN STRUCTURE; SKIN ULCER; SURGICAL INFECTION; UNITED STATES;

EID: 84879084752     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e318279ee69     Document Type: Review

References (25)

1. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother. 1999;44(suppl A):19-23.
2. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for Industry: Uncomplicated and Complicated Skin and Skin Structure InfectionsVDeveloping Antimicrobial Drugs for Treatment. Rockville, MD: US Department of Health and Human Services; 1998.
3. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460-1468.
4. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis. 2002;35:381-389.
5. Li JZ, Willke RJ, Rittenhouse BE, et al. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt). 2003;4:57-70.
6. Deery HG II. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect Dis Clin North Am. 1998;12:935-949.
7. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis. 2001;33(suppl 2):S84-S93.
8. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs. 2003;63:1459-1480.
9. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis. 1999;34:65-72.
10. Summanen PH, Talan DA, Strong C, et al. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis. 1995;20(suppl 2):S279-S282.
11. Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother. 2003;51(suppl 2):ii37-ii44.
12. Boyce JM. Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol. 1992;13:725-737.
13. Stevens DL, Bisno AL, Chambers HFet al, for the Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.
14. May AK. Skin and soft tissue infections. Surg Clin North Am. 2009;89:403-420.
15. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 2007;57:7-13.
16. Awad SS, Elhabash SI, Lee L, et al. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg. 2007;194:606-610.
17. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt). 2005;6:283-295.
18. Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. 2005;11:928-930.
19. Rennie RP, Jones RN, Mutnick AH, for the SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis. 2003;45:287-293.
20. Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008;29:160-169
21. Public WelfareVProtection of Human Subjects; 45CFR 46 §46.101.
22. Comparison of antibacterial spectra. In: Gilbert DN, Moellering RC Jr, Eliopoulos GM, et al, eds. The Sanford Guide to Antimicrobial Therapy 2011: Forty-First Edition. Sperryville, VA: Antimicrobial Therapy Inc; 2011.
23. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(suppl 3):iii35-iii44.
24. Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents. 2009;34(suppl 1):S2-S7.
25. May AK, Stafford RE, Bulger EM, et al. Treatment of complicated kin and soft tissue infections. Surg Infect (Larchmt). 2009;10:467-499.